{"id":"fractionated-blood-products-transfusion","safety":{"commonSideEffects":[{"rate":null,"effect":"Transfusion-related acute lung injury (TRALI)"},{"rate":null,"effect":"Febrile non-hemolytic transfusion reaction"},{"rate":null,"effect":"Allergic reaction"},{"rate":null,"effect":"Hemolytic transfusion reaction"},{"rate":null,"effect":"Transfusion-associated circulatory overload (TACO)"},{"rate":null,"effect":"Infection transmission risk"}]},"_chembl":{"chemblId":"CHEMBL2108414","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This therapeutic approach involves the transfusion of separated blood components rather than whole blood, allowing targeted replacement of deficient factors. It is used to correct coagulopathy, thrombocytopenia, anemia, and hypovolemia in trauma, surgery, and critical care settings. The fractionation allows precise dosing of needed components while minimizing volume overload and immune complications.","oneSentence":"Fractionated blood products transfusion replaces or supplements specific blood components (plasma, platelets, red blood cells, clotting factors) to restore hemostasis and oxygen-carrying capacity in patients with deficiencies or massive hemorrhage.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:24.346Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Massive hemorrhage and hemorrhagic shock"},{"name":"Coagulopathy secondary to trauma or surgery"},{"name":"Thrombocytopenia with active bleeding"},{"name":"Severe anemia requiring transfusion support"}]},"trialDetails":[{"nctId":"NCT04431999","phase":"PHASE3","title":"Evaluation of a Transfusion Therapy Using Whole Blood in the Management of Coagulopathy in Patients With Acute Traumatic Hemorrhage","status":"COMPLETED","sponsor":"Direction Centrale du Service de Santé des Armées","startDate":"2021-12-04","conditions":"Trauma, Acute Hemorrhage, Coagulopathy","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Fractionated blood products transfusion","genericName":"Fractionated blood products transfusion","companyName":"Direction Centrale du Service de Santé des Armées","companyId":"direction-centrale-du-service-de-sant-des-arm-es","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fractionated blood products transfusion replaces or supplements specific blood components (plasma, platelets, red blood cells, clotting factors) to restore hemostasis and oxygen-carrying capacity in patients with deficiencies or massive hemorrhage. Used for Massive hemorrhage and hemorrhagic shock, Coagulopathy secondary to trauma or surgery, Thrombocytopenia with active bleeding.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}